Results 281 to 290 of about 3,310,854 (363)

Eight‐Year Experience of Hedgehog Pathway Inhibitors at Three Tertiary Referral Centres in the Australian State of Victoria

Australasian Journal of Dermatology, EarlyView.
ABSTRACT This retrospective analysis of Hedgehog inhibitor treatment in 32 patients with Gorlin syndrome, locally advanced and metastatic basal cell carcinoma (BCC) at three tertiary referral centres in Victoria, Australia from April 2017 until 30 June 2024 demonstrated an 84% overall objective response rate (partial and complete response combined ...
Christian Gan, Nicholas Manuelpillai, Peter Foley, Christopher McCormack, Michelle S. Goh   +4 more
wiley   +1 more source

Use of oral retinoids in the perioperative period by surgical specialty: a literature review. [PDF]

Arch Dermatol Res
Truax L, Hendrixson M, Naqvi J, Trevino J.   +3 more
europepmc   +1 more source

Psychosocial Determinants and Atopic Dermatitis Outcomes: A Cross‐Sectional Study From an Australian Paediatric Centre

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) significantly impacts quality of life, with well‐documented physical and psychological consequences. While disease burden is well characterised, the influence of psychosocial determinants on AD outcomes remains underexplored. This study examines these factors in an Australian paediatric population.
Ashling Courtney, Anousha Yazdabadi, Emily Schembri, Adrian J. Lowe, Crystal Williams, John C. Su   +5 more
wiley   +1 more source

Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database. [PDF]

J Dermatol
Ma Y, Chachin M, Hirose T, Nakamura K, Shi N, Hiro S, Imafuku S.   +6 more
europepmc   +1 more source

CT‐P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study

Allergy, EarlyView.
This study investigated the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria. Therapeutic equivalence between CT‐P39 and ref‑OMA (300 mg) was demonstrated by the primary endpoint – confidence intervals of the treatment difference in mean change ...
Sarbjit S. Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan   +16 more
wiley   +1 more source

Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha

Allergy, EarlyView.
MOv18 IgE, the first‐in‐class IgE antibody targeting the cancer antigen folate receptor alpha (FR⍺) showed early signs of efficacy and was well tolerated in a first‐in‐human clinical trial, with transient urticarial skin reactions as the most common toxicity.
Chara Stavraka, Jitesh Chauhan, Silvia Crescioli, Sheila M. McSweeney, Amy Pope, Cheryl Gillett, Ashley Di Meo, Ioannis Prassas, Roman Laddach, Katie Stoker, Alexandra J. McCraw, Rebecca Adams, Thomas J. Tull, Nabeel Naban, Zena Willsmore, Kristina V. Semkova, Clive E. H. Grattan, John McGrath, Stephen J. Till, Christopher J. Corrigan, Rebecca Kristeleit, Sophia Tsoka, Eleftherios P. Diamandis, Katie E. Lacy, Sarah Pinder, Debra H. Josephs, James Spicer, Heather J. Bax, Sophia N. Karagiannis   +28 more
wiley   +1 more source

The Impact of Surgery on Quality of Life in Hidradenitis Suppurativa: Results from a Prospective Single-Center Study. [PDF]

Life (Basel)
Ocker L, Abu Rached N, Koller A, Frost C, Käpynen R, Bechara FG.   +5 more
europepmc   +1 more source

Enteropathic SAPHO Syndrome in Ulcerative Colitis Responsive to Bisphosphonates. [PDF]

Case Rep Rheumatol
Phillipps J, Mumtaz S, Valecha J, Stanborough RO, Berianu F, Abate E, Majithia V.   +6 more
europepmc   +1 more source

Economic Impact of Allergic Diseases and Asthma—The HEAD Pan‐European Registry

Allergy, EarlyView.
This registry‐based study demonstrates the substantial economic burden of allergic diseases across Europe with a high degree of heterogeneity between countries. Treatments and specialist visits are the primary drivers of healthcare costs. Asthma poses the highest disease burden.
Ioana Agache, Maria Torres, Ibon Eguiluz‐Gracia, Elena Bradatan, Kamal El Abd, Maria Beatrice Bilo, Federica Rivolta, Andrea Sangalli, Roxana Bumbacea, Selda Ali, Dario Antolin, Águeda Concepción Lario Cuenda, Vicente Albéndiz, Maria Miguel Oliveira, Paulo Jorge Nogueira, Loreto Carmona, HEAD Study Group, Audrey Courtois, Helene Simonis, Romain Nonis, Michel Crine, Christine Leon, Carine Sohy, Virgine Doyen, Andre Benedicte, Charles Pilette, Irina Kaidalina, Christophe Goubau, Katerina Absolonova, Ales Zlamal, Olga Zlamalova, Phillip Globig, Margitta Worm, Angelika Sasien, Mehrak Yoosefi Moridani, Federica Rivolta, Valentina Longo, Andrea Sangalli, Francesco Murzilli, Carmela Montera, Mario Lo Schiavo, Corina Bocsan, Corina Ureche, Cristian Budica, Diana Deleanu, Adriana Muntean, Agnes Sandor, Carmen Teodora Dorican, Camelia Berghea, Florin‐Dan Popescu, Irina Bucur, Mariana Vieru, Laia Ferré, Alicia Habernau, Agueda Larios, Jose Julio Laguna, Natalia Pérez Sánchez, Oscar Asensio, Roser Ayats, Helena Larramona, Beatriz Torres‐Pérez, Alica Barra‐Castro, Sergio Quevedo, Teresa Bracamonte, Manuel Diaz, Miguel Tortajada, Dah Tay Jang   +66 more
wiley   +1 more source